通过MET激活的Wnt冷凝原药逆转基因驱动的NSCLC中MET介导的耐药性
Na Liu1, Xiaoqiang Zheng1,2, Jin Yan3,4
1Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, P. R. China.
在非小细胞肺癌 (NSCLC) 中,MET放大导致对EGFR向治疗的耐药性. 一种新的Wnt抑制剂,WntSI,通过向Wnt/β-catenin通路来克服这种抵抗,提供了一种新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物开发 药物开发
背景情况:
- 在非小细胞肺癌 (NSCLC) 中,MET放大是对EGFR-氨酸激酶抑制剂 (TKI) 获得耐药性的关键机制.
- 由于反循环激活Wnt/β-catenin通路,MET抑制剂显示出有限的疗效,促进癌细胞存活.
研究的目的:
- 调查Wnt/β-catenin通路在MET放大驱动的EGFR-TKI抗性的作用.
- 开发一种新的治疗策略来克服这种抵抗.
主要方法:
- 设计和合成WntSI,一种使用液-液相分离 (LLPS) 和与Wnt抑制剂 (CA) 结合的MET/pH反应性 (Tyr-Pep) 的前药物.
- 在细胞系衍生和患者衍生瘤异种移植 (PDX) 鼠标模型中评估WntSI疗效的EGFR突变NSCLC与MET放大.
主要成果:
- 在Tyr-Pep的MET介导酸化过程中,WntSI有效地抑制了Wnt/β-catenin通路,导致WntSI分解.
- 在临床前模型中,WntSI在克服对EGFR-TKIs获得的耐药性方面表现出显著的有效性.
- 该战略保持了高的生物安全性.
结论:
- 通过生物响应的LLPS准Wnt/β-catenin通路是克服NSCLC中MET放大介导耐药性的有希望的策略.
- WntSI代表了癌症治疗的创新前药方法.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Non-Canonical Wnt Signaling Pathways
Canonical Wnt Signaling Pathway
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
